Stock Isn’t Cheap but Still Worth Buying? Three Hard Reasons Behind Eli Lilly Explained

Life Science

Dark Horse in the Weight-Loss Drug Arena? Viking Therapeutics Has Potential Upside of Over 200%

Life Science

GLP-1s and AI Are the Big Themes Behind These 5 Top-Rated Health Care Picks for 2026

Life Science

Want to Build Real Wealth in the Healthcare Sector? These Stocks Are Worth Considering

Life Science

Bristol Myers Squibb Beats on Q1 Sales, Profit; Stock Jumps 5% as Growth Portfolio Shines

Life Science

How to Invest a $1,000 Tax Refund? Two TSX Stocks Worth Watching

Life Science, Technology

Shorted-to-The-Hilt KalVista Rockets 39% as Chiesi Swoops in With $1.9bn Cash Bid

Life Science

Biogen’s Q1 Net Profit Rises 19%, Driven by Growth Products

Life Science

High-Yield Healthcare Plays: MPT and Pfizer Offer 7% and 6.4% Dividends as Markets Turn Choppy

Life Science, Real Estate

From Weight Loss to Cancer Treatment Drugs, Eli Lilly Has More Than One Ace in the Hole

Life Science

Organon Shares Extend Rally as India’s Sun Pharma Strikes $11.75 Billion All-Cash Deal

Life Science

Teva Pharmaceuticals to Release Quarterly Report, Analysts Suggest Waiting for Post-Earnings Purchase

Life Science

Buffett’s UnitedHealth Bet Pays Off as Insurer Crushes Q1 Estimates

Financial Service, Life Science

Can the New Weight-Loss Drug Foundayo from Eli Lilly Replicate Its Blockbuster Success? Early Data Raises Market Concerns

Life Science

Three Healthcare Stocks with Long-Term Competitive Moats

Life Science